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ABSTRACT Although the CD34 antigen is widely used in
the identification and purification of hemopoietic stem and
progenitor cells, its function within hemopoiesis is unknown.
We have investigated this issue by ectopically expressing
human (hu) CD34 on the surface of murine hemopoietic cells.
Forced expression of hu-CD34 in the thymocytes of transgenic
mice did not appear to affect the development, maturation, or
distribution of murine T cells but did significantly increase
their ability to adhere to bone marrow stromal layers of
human but not mouse origin. Ectopic expression of hu-CD34
on murine 416B cells, a multipotential progenitor that ex-
presses murine CD34, yielded similar results. In both cases
hu-CD34-dependent adhesion was enhanced by molecular
engagement of the hu-CD34 protein using anti-CD34 antibod-
ies. These results provide evidence that CD34 promotes the
adhesive interactions of hemopoietic cells with the stromal
microenvironment of the bone marrow thereby implicating
CD34 in regulation and compartmentalization of stem cells.
We propose that CD34 regulates these processes in part via an
indirect mechanism, signaling changes in cellular adhesion in
response to molecular recognition of an as yet unidentified
stromal CD34 counterreceptor or ligand.
Expression of the stem cell antigen CD34 is a defining
hallmark of hemopoietic stem cells and progenitors and CD34
is therefore widely used as a tag for the enumeration, isolation,
and manipulation of these cells (1-3). Despite this extensive
use, the normal function of the CD34 molecule within hemo-
poiesis has remained enigmatic. Human (hu) and murine
CD34 homologues are highly conserved in their protein coding
regions, which predict a type I transmembrane protein (4, 5).
The cytoplasmic domains of the human and mouse proteins
share 90% amino acid identity; the transmembrane and C-
terminal regions of the extracellular domains are also well
conserved with 73-82% amino acid identity. The N-terminal
portions of the extracellular domains are the least well con-
served regions of the molecule (45% amino acid identity).
Both hu-CD34 and mouse CD34 are extensively modified
posttranslationally by carbohydrate and are highly sialylated
(6, 7). This pattern of processing provides different epitopes
for the various CD34 monoclonal antibodies and may well be
relevant to the function of the molecule (8). The expression
pattern of CD34 is also conserved between human and mouse.
Thus, in addition to being expressed selectively during human
(1-3, 8) and murine (4, 7) hemopoiesis on stem cells and
progenitors, both mouse CD34 and hu-CD34 are expressed
outside the hemopoietic system on vascular endothelium (9,
10), high endothelial venules (HEVs) (8, 11), and some
fibroblasts (4, 12). This distribution of CD34 implies a function
outside of hemopoiesis. CD34 on HEVs appears to be pro-
cessed differently from that on hemopoietic cells and vascular
endothelium (8) and may provide an adhesive binding site
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recognized by L-selectin on circulating lymphocytes (11). In
this report, we have investigated the function of CD34 during
hemopoiesis by ectopically expressing hu-CD34 in murine
hemopoietic cells.
MATERIALS AND METHODS
Hu-CD34-Expressing Transgenic Mice. pCD2-hu-CD34; a
1.5-kb Not I/HindIII fragment containing the entire hu-CD34
coding region (5), was isolated from irH3M-CD34 and inserted
into the BamHI site of p,BG-CD2 using Bgl II synthetic linkers.
The Kpn I/Not I fragment was used to produce the three lines
of transgenic mice used in this study (13).
Hu-CD34-Expressing 416B Cells. pMT-hu-CD34; the Kpn
I/Not I fragment described above, was inserted via Bgl II
synthetic linkers into the Bgl II site of MTIIazCAT, which
contains promoter sequences from the human metallothionein
Ila gene from -302 to +76 bp, with the AP-1 binding site at
-106 to -97 mutated (14). A neomycin-resistance gene driven
by the herpes simplex virus thymidine kinase promoter was
inserted downstream of the simian virus 40 splice and polya-
denylylation sequences in the same orientation as the CD34
cDNA. Stably transfected clones of 416B cells were obtained
by electroporation followed by drug selection as described
(15).
Immunophenotypic Analysis. Single cell suspensions of
thymocytes were obtained from the thymuses of 8- to 10-week-
old sex-matched mice. Thymocytes or 416B cells were incu-
bated with an Fcy blocking reagent, CD16/CD32 (Pharmin-
gen), before staining with antibodies directly conjugated to
either fluorescein isothiocyanate (FITC) or R-phycoerythrin
(R-PE); subclass-specific antibody controls were included.
Flow cytometric analyses were carried out with a FACScan
(Becton Dickinson).
Adhesion Assays. Human stromal cultures were grown for
4-6 weeks from the mononuclear fraction of bone marrow
originally plated in a 25-cm2 tissue culture flask at 107 cells per
10 ml in a medium 10% fetal calf serum (FCS), 10% horse
serum, and 2 ,urM methylprenisolone (Upjohn) and fed weekly.
The preformed mouse stromas were also 4-6 weeks old. These
were established as follows: femurs were removed from 8- to
10-week-old BD F1 mice and flushed into Fischer's medium
(Life Technologies, Grand Island, NY), cells were centrifuged
and resuspended in Fischer's medium supplemented with 20%
horse serum and 1% hydrocortisone succinate (Sigma) to a
final concentration of one femur equivalent per 10 ml of
medium, and 10-ml aliquots were dispensed into 25-cm- tissue
culture flasks. Cultures were fed at weekly intervals by demide-
population. The MS5 cell line (16) was cultured in flasks
precoated with 1% gelatin (Sigma) in the same medium used
to grow human bone marrow cultures. For adhesion assays,
Abbreviations: hu, human; HEV, high endothelial venule; FITC,
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hemopoietic cells were suspended in a medium (Life Tech-
nologies), containing 15% FCS (PAA Laboratories, Durham,
U.K.) at a concentration of 1 X 106 cells per ml and incubated
on the preformed stromal layers for 2 h at 37°C before washing
three times with Hanks' buffered saline solution (HBSS; Life
Technologies) to remove nonadherent cells. The latter were
centrifuged, resuspended in phosphate-buffered saline (PBS),
and counted with a hemocytometer. Preliminary experiments
showed that adhesion was maximal at 1 h. A 2-h end point
was used in all subsequent experiments, as in our previous
studies on progenitor cell adhesion to bone marrow stroma
(17).
Antibody Experiments. Cells were washed in PBS/0.1%
bovine serum albumin (Sigma), centrifuged, and resuspended
at 1 x 106 cells per 100 ,.tl. Cells were then incubated with 15
,ug each of unlabeled anti-hu-CD34 antibodies, HPCA-2,
QBend 10, and Immu 133 (8) or with 45 jig of control mouse
IgGI for 30 min on ice. At the end of this incubation period,
4.75 ml of a-MEM medium supplemented with 15% FCS was
added to the cells. The cells were then added to preformed
primary human bone marrow stromas or to the MS5 cell line
and incubated at 37°C for 2 h. Nonadherent cells were washed
off using HBSS, and the cells were counted with a hemocy-
tometer.
RESULTS
Targeting CD34 Expression to T Lymphocytes. Hu-CD34
expression was targeted to the T-cell compartment of trans-
genic mice using an expression vector containing the CD2
locus control region (18) (Fig. 1A). Greater than 95% of
CD2-reactive T cells expressed hu-CD34 (Fig. 1B) and pro-
cessed it similarly to human hemopoietic cells (Fig. 1C) as
judged by reactivity to a panel of monoclonal antibodies whose
recognition of CD34 varies according to its modification by
carbohydrate. Class I epitopes are sensitive to sialidase (neur-
aminidase), class II epitopes are destroyed by glycoprotease
(Pasteurella haemolytica), while class III epitopes are resistant
to these enzymes. CD34 antibodies selectively binding to these
three classes of epitopes react equivalently with transgenic
mouse thymocytes and human KG-IA cells (Fig. 1C); KG-1A
is a human leukemia cell line considered to represent the
lymphomyeloid stem cell compartment (19). We therefore
infer that mouse thymocytes process the hu-CD34 molecule
similarly to human hemopoietic cells. The ectopic expression
of hu-CD34 did not alter either the intrathymic development
of CD3+ T cells (Fig. 1D) or the relative distribution of thymic
T-cell subsets as defined by CD4 and CD8 expression (Fig.
1E). Numbers of CD3+ T cells and CD4+ or CD8+ T-cell
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FIG. 1. Targeting hu-CD34 expression to the
murine T-cell compartment. (A) pCD2-hu-CD34
used for murine transgenesis. A hu-CD34 cDNA
(solid box) encoding its own translational initia-
tion and termination codons is transcribed and
processed using human 0-globin promoter,
splice, and polyadenylylation sequences (open
boxes); high level T-cell-specific expression is
directed by the human CD2 LCR (hatched box).
(B) Flow cytometric analysis of hu-CD34 expres-
sion. Thymocytes were simultaneously labeled
with anti-hu-CD34 [FITC-conjugated-HPCA-
2(8GI2); Becton Dickinson] and anti-mouse
CD2 (R-PE-conjugated-RM2-5; Pharmingen)
antibodies. Note that nearly all the CD2+ trans-
genic thymocytes express hu-CD34. (C) Post-
translational modification analysis of hu-CD34 in
transgenic thymocytes. Thymocytes from CD2-
huCD34 transgenic mice were labeled with class
I (Immu 133-R-PE; Immunotech, Luminy,
France), class II (Qbend 10-FITC; Quantum
Biosciences, Cambridge, U.K.), and class III
(HPCA-2-FITC) anti-hu-CD34 antibodies;
CD34 epitopes are classified according to neur-
aminidase and glycoprotease sensitivity (see text
for details). Similar flow cytometric profiles are
obtained from CD2-hu-CD34 thymocytes and
human hemopoietic progenitor cells (KG-1A).
(D) Cell surface expression of the CD3 compo-
nent of the T-cell receptor. Thymocytes from
control and transgenic mice display similar flow
cytometric profiles when vitally stained with anti-
mouse CD3 (biotin-conjugated 145-2C11;
PharMingen) antibodies. Antibody labeling was
visualized using R-PE-conjugated streptavidin
(PharMingen). (E) Analysis of thymic T-cell sub-
sets. Transgenic and control thymocytes were
simultaneously labeled with anti-mouse CD4
(L3T4-R-PE; PharMingen) and CD8 (53-6.7-
FITC; PharMingen). Flow cytometry analysis
showed no differences in the relative numbers of
double-negative, single-positive, and double-
positive thymocytes.
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subsets in blood, spleen, and lymph nodes of transgenic mice
were also in the normal range (data not shown).
CD34 Promotes Adhesion of Thymocytes to Bone Marrow
Stroma. We next examined the potential involvement of CD34
in the adherence of hemopoietic cells within the stromal
microenvironment of the bone marrow by testing whether the
expression of human CD34 by murine thymocytes could alter
their adherence to bone marrow stromal layers in vitro. First,
we cocultured known numbers of thymocytes from transgenic
or control animals with stromal layers prepared from normal
human bone marrow. Nonadherent thymocytes were recov-
ered by sequential washing of the stromal layers and the
percentages of adherent vs. nonadherent thymocytes were
determined. The results obtained from six independent exper-
iments using stromal layers derived from different individuals
are presented in Fig. 2; the percentages of thymocytes bound
to human bone marrow stroma are considerably higher in the
transgenic animals (42-58%; mean, 50%; SD, 6%) than in the
nontransgenic littermates (4-30%; mean, 13%; SD, 10%).
Hu-CD34 transgenic thymocytes adhere predominantly to
fibroblast-like stromal cells, whereas most of the adhesion
observed with control thymocytes is instead to large blanket-
like cells (Fig. 3, arrow); the frequency of these cells in
different stromal layers varies considerably and may underlie
the variation in background levels of adhesion observed with
control thymocytes. Note that hu-CD34 transgenic thymocytes
do not exhibit any enhanced adhesion to murine bone marrow-
derived stromal cells (Fig. 4); this apparent species restriction
in the ability of hu-CD34 to recognize its cognate cell adhesion
molecule (CAM) ligand presumably explains the normal de-
velopment and distribution of T cells in hu-CD34 transgenic
mice.
CD34-Dependent Adhesion of Multipotential Hemopoietic
Progenitor Cells. We next examined whether the CD34-
dependent stromal adhesion we observed was necessarily
dependent on the T-cell background used in our experiments
or was also a feature of hemopoietic progenitor cells that
characteristically express the CD34 antigen. The rarity and
heterogeneity of normal hemopoietic stem and progenitor
cells preclude their straightforward use in quantitative adhe-
sion assays. The murine cell line 416B has been derived from
long-term cultures of virally infected mouse bone marrow (20),
expresses the murine CD34 antigen (4, 15), and is considered
representative of the multimyeloid progenitor compartment.
We transfected murine 416B cells with a eukaryotic expression
vector in which the hu-CD34 cDNA had been placed under
control of the metallothionein promoter (Fig. SA). The clones
obtained (416B-hu-CD34) constitutively expressed appropri-
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FIG. 2. Adherence of transgenic and control thymocytes to hemo-
poietic stromal layers. Percentages of transgenic (solid bars) or control
(open bars) thymocytes that adhere to human bone marrow-derived
stromal layers in six independent experiments are shown. Human
stromal layers used in each experiment are from different individuals
and results were obtained with two independent lines of CD2-hu-
CD34 transgenic mice.
Transgenic Control
FIG. 3. Photomicrographs of transgenic and control thymocytes
(small bright cells) adhered to human bone marrow stroma (fibroblast-
like cells). Visual inspection of stromal layers reveals microheteroge-
neity in thymocyte binding in both transgenic and control experiments;
fields shown are typical of the general patterns in binding observed.
Arrow identifies a large blanket cell.
ately posttranslationally modified hu-CD34 molecules (Fig.
5B; data not shown); the level of murine CD34 expression on
these cells was unaltered (Fig. SB). We next compared the
ability of 416B-hu-CD34 vs. untransfected 416B cells to bind
to human bone marrow stromal layers. The results from four
independent experiments are presented in Fig. 5C and show
that, like CD2-hu-CD34 transgenic thymocytes, 416B-hu-
CD34 cells bind human stromal layers significantly better than
control 416B cells.
Mechanisms of CD34-Dependent Adhesion. Taken together
these results suggest that the function of CD34 on the surface
of hemopoietic cells relates to their adhesive interactions with
the stromal microenvironment of the bone marrow. CD34 may
achieve this simply and directly (Fig. 6A, model 1) by inter-
acting with a stromal-associated CAM. Alternatively, CD34
may promote adhesion (model 2) by signaling changes in the
profile of CAMs at the cell surface after recognition of a
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FIG. 4. Species restriction in CD34-dependent adhesion. Percent-
ages of transgenic (solid bars) or control (open bars) thymocytes that
adhere to either mouse bone marrow-derived stromal layers (mo-
stroma) or murine hemopoietic stromal cell lines (mo-MS5) are shown.
Mean binding values obtained in the human stromal adhesion assays
shown in Fig. 2 are included for comparison (hu-stroma). Error bars
show standard deviations of the means.
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FIG. 5. Ectopic expression of hu-CD34 in murine hemopoietic
progenitors. (A) pMT-hu-CD34. The hu-CD34 cDNA (see Fig. 1) was
placed under the control of the human metallothionein Ila promoter
(open box) and simian virus 40 (SV40) splice and polyadenylylation
(polyA) signals (stippled box). Drug resistance was provided by a
TKneo cassette (shaded box). (B) Flow cytometric analysis. Trans-
fected and control 416B cells were labeled indirectly with an anti-
mouse CD34 rabbit polyclonal antibody (Left) or an anti-hu-CD34
antibody (HPCA-2-FITC) (Rig/it). Note that expression of murine
CD34 was unaffected in the 416B-hu-CD34 cells. (C) Adherence to
human bonej marrow stroma. Percentages of 416B-hu-CD34 (solid
bars) and control 416B (open bars) cells that adhere are shown.
stromally associated CD34 ligand or receptor. We have inves-
tigated these possibilities by analyzing the effect of anti-CD34
antibodies on the binding capacity of transgenic thymocytes.
The results presented in Fig. 6B show that pretreatment of
transgenic mouse thymocytes with a mixture of class 1, 2, and
3 anti-hu-CD34 antibodies does not abrogate their binding
capacity but instead significantly increases it; increased binding
was not observed when cells were pretreated with isotype-
matched control antibodies. Increased adhesion was also ob-
served when hu-CD34-transfected 41 6B cells were treated with
anti-hu-CD34 antibodies (data not shown). In this regard, it is
interesting to note that the homotypic adhesion of CD34-
expressing KG-1 cells has recently been reported to also
increase as a result of the engagement of anti-CD34 antibodies
(21, 22). Taken together, our results are most easily reconciled
with the second of the two models and raise the possibility that
the stromal adhesion observed in transgenic thymocytes is
mediated by modulation of murine CAMs in response to
CD34-mediated signaling. These murine CAMs should pre-
sumably facilitate binding to mouse as well as human stroma,
and we therefore asked whether hu-CD34 transgenic thymo-
cytes, pretreated with anti-hu-CD34 antibodies, had acquired
the ability to bind to mouse stromal layers. The results
presented in Fig. 6C show that antibody treatment causes an
increase in binding of transgenic thymocytes to murine stroma,
in accord with our hypothesis.
DISCUSSION
Adherence of hemopoietic stem cells and progenitors to the
stromal cell bone marrow microenvironment is considered to
be a key component of the developmental sequestration and
regulation of these cells (23-25). Several different molecules
are likely to be involved in what is probably a multicomponent
or cascading adhesive interaction. The selective expression of
CD34 on the surface of hemopoietic progenitors has led to the
speculation that it may be involved in this process, although,
paradoxically, most speculation has centered around the no-
tion that stem cell CD34 functions as an antiadhesion mole-
cule. This hypothesis has stemmed from both the rapid down-
regulation of CD34 that accompanies the cytokine-mediated
upregulation of vascular endothelial adhesion molecules in
vitro (26) and in vivo (27) and from the structural and
biochemical features of the N terminus of the CD34 molecule,
which is extensively glycosylated with both N- and 0-linked
carbohydrates including sialic acid [reviewed in ref. 9]. This
region is therefore predicted to adopt the conformation of an
extended rod, protruding a considerable distance above the
cell membrane and presenting a net negative charge. By
analogy with N-CAM (28) and CD43/leukosialin (29), a
hemopoietic sialomucin with some structural similarities to
CD34, a cellular halo of sialic acid-dependent negative charge
was postulated to function as a barrier to cell-cell interaction
(26). In such a scheme, CD34 function is presumed to be
primarily dependent on the overall conformation and charge
of the N terminus rather than its precise amino acid sequence.
Adhesive functions of molecules are likely to be very context
dependent and our results demonstrate a pro adhesive role for
the CD34 sialoglycoprotein in the interaction of hemopoietic
and stromal cells. Furthermore, our observation that ectopic
expression of the hu-CD34 molecule confers increased binding
to human stromal cells and cell lines but not to their murine
counterparts implies that the adhesive function of CD34 is not
simply attributable to the negatively charged rod-like confor-
mation of its N terminus but rather involves specific recogni-
tion of the CD34 molecule, presumably by a stromally associ-
ated counterreceptor or ligand. A likely explanation for the
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FIG. 6. Models for CD34-mediated cellular adhesion. (A) (Left) Model 1: CD34 functions simply and directly as an avid CAM. (Rig/lt) Model
2: adhesion is promoted via modulations in the cell surface profile of murine adhesion molecules (either upregulation of adhesive CAMs or
downregulation of antiadhesion molecules) in response to hu-CD34-mediated intracellular signaling; the initial CD34 ligand-receptor interaction
may itself be an adhesive interaction. (B) Effect of anti-hu-CD34 antibodies (abs) on adherence of transgenic (tg) and control (non-tg) thymocytes
to human bone marrow stroma. A mixture of class I, II, and III anti-hu-CD34 antibodies was used and the results of two independent expcriments
are shown. (C) Effect of anti-hu-CD34 antibody mixture on adherence of thymocytes to murine hemopoietic stromal cell line MS5.
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failure of hu-CD34 to increase binding of hemopoietic cells to
murine stroma is that the hu-CD34 molecule is unable to
recognize the murine CD34 counterreceptor ligand. This
would provide a plausible explanation for the apparent nor-
mality of the T-cell compartment in CD2-hu-CD34 transgenic
mice and would be consistent with the observation that
hu-CD34 and mouse CD34 diverge the most in the N-terminal
portions of their extracellular domains where they share only
45% amino acid identity (4, 5). Our observation that engage-
ment of the hu-CD34 molecule by anti-CD34 antibodies
facilitates the binding of hemopoietic cells to bone marrow-
derived stromal layers also implicates molecular recognition of
the extracellular domain of CD34 as a critical component of
CD34-dependent adhesion. The fact that anti-hu-CD34 anti-
bodies enhance the ability of hu-CD34-expressing murine
hemopoietic cells to bind to murine stromal layers (in the
absence of antibody addition, these cells show no increased
binding relative to non-hu-CD34-expressing controls) leads us
to speculate that CD34 promotes adhesion in this context by
signaling changes in the cell surface profile of murine CAMs
in response to molecular recognition of its extracellular do-
main. The high degree of evolutionary conservation in the
intracellular domains of hu-CD34 and mouse CD34 (90%
amino acid identity) (4, 5) as well as recently reported exper-
imental evidence that anti-CD34 antibodies promote the ho-
motypic adhesion of the CD34-expressing KG-1 cells (22, 23)
also support a role for CD34 in adhesive signaling. However,
CD34 molecules may also possess direct CAM-like activity
since preliminary experiments suggest that CD34 lacking an
intracellular C-terminal tail still facilitates adhesion to stroma
(L.H. and G.M., unpublished observations).
Identifying the molecule in human bone marrow stroma that
is normally recognized by CD34 may suggest strategies for
stem cell manipulation and mobilization. Some biochemical
evidence has indicated that L-selectin can bind sulfated CD34
derived from HEVs (11), suggesting that leukocyte adherence
to, and/or migration across, HEVs might involve CD34 as well
as the major L-selectin ligand on HEVs provided by Sgp5O
(Gly CAM1) (30). Several lines of evidence rule out L-selectin
as the likely bone marrow stromal ligand for CD34. Firstly,
L-selectin does not bind to hemopoietic CD34 on KG-1 cells
(21, 31). Secondly, the antibody MECA79 recognizes a sul-
fated carbohydrate on L-selectin ligands and blocks binding
(32), but we find that it does not influence the adhesion of
hu-CD34 transgene-expressing murine cells to human bone
marrow stroma (L.H., unpublished observation). Finally,
CD34 molecules on HEVs appear to be glycosylated differ-
ently from those on vascular and hemopoietic cells (8, 10).
These differences in carbohydrate modification may well in-
fluence ligand recognition, in which case glycosylation-
dependent recognition would have to be accommodated in any
strategy for cloning the CD34 counterreceptor which uses
CD34 itself as a component of the assay.
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